Asian consensus report on functional dyspepsia

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 626-641

  Miwa, Hiroto ^a   Ghoshal, Uday Chand ^e   Fock, Kwong Ming ^f   Gonlachanvit, Sutep ^h   Gwee, Kok Ann ^g   Ang, Tiing Leong ^f   Chang, Full Young ^k   Hongo, Michio ^b   Hou, Xiaohua ^m   Kachintorn, Udom ⁱ   Ke, Meiyun ⁿ   Lai, Kwok Hung ^l   Lee, Kwang Jae ^p   Lu, Ching Liang ^k   Mahadeva, Sanjiv ^t   Miura, Soichiro ^c   Park, Hyojin ^q   Rhee, Poong Lyul ^r   Sugano, Kentaro ^d   Vilaichone, Ratha korn ^j   Wong, Benjamin C Y ^o   Bak, Young Tae ^s   more..

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^f CHANGI GENERAL HOSPITAL   (Singapore)

^g Dept Medicine Endocrinol Diabet   (Singapore)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

^k TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^l NATIONAL YANG MING UNIVERSITY   (Taiwan)

^m HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

ⁿ PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^o UNIVERSITY OF HONG KONG   (Hong Kong)

^p Ajou University School of Medicine   (South Korea)

^q Yonsei University College of Medicine   (South Korea)

^r Sungkyunkwan University School of Medicine   (South Korea)

^s Korea University College of Medicine   (South Korea)

^t UNIVERSITY OF MALAYA   (Malaysia)

more..

Author keywords

Asia; Diagnosis; Epidemiology; Functional dyspepsia; Management; Pathophysiology

Indexed keywords

AMITRIPTYLINE; BUSPIRONE; CINITAPRIDE; CISAPRIDE; DOMPERIDONE; FLUOXETINE; ITOPRIDE; METOCLOPRAMIDE; MIANSERIN; MOSAPRIDE; PROTON PUMP INHIBITOR; SULPIRIDE; TANDOSPIRONE; TRIMEBUTINE;

ABDOMINAL RADIOGRAPHY; ALGORITHM; ARTICLE; ASIAN; BLOATING; BLOOD CELL COUNT; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DEPRESSION; DIET; DRUG EFFICACY; DRUG MECHANISM; DYSPEPSIA; E-MAIL; ENDOSCOPY; ENVIRONMENTAL FACTOR; EPIGASTRIC BURNING; EPIGASTRIC PAIN; FECES ANALYSIS; FUNCTIONAL DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HERBAL MEDICINE; HUMAN; IRRITABLE COLON; LOW DRUG DOSE; MEDICAL LITERATURE; NAUSEA; NOMENCLATURE; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; RISK BENEFIT ANALYSIS; SLEEP DISORDER; STOMACH CANCER; STOMACH DISTENSION; STOMACH EMPTYING; VOMITING;

EID: 84863338128     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07037.x     Document Type: Article

References (196)

1. Colin-Jones D, Bloom B, Bodemar G etal. Management of dyspepsia: report of a working party. Lancet 1988; 1: 576-9.
2. Murphy MK, Black NA, Lamping DL etal. Consensus development methods, and their use in clinical guideline development. Health Technol. Assess. 1998; 2: i-iv, 1-88.
3. Atkins D, Best D, Briss PA etal. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
4. Tack J, Talley NJ, Camilleri M etal. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
5. Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am. J. Gastroenterol. 2008; 103: 1241-8.
6. Jiang X, Locke GR 3rd, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut 2008; 57: 756-63.
7. Manabe N, Haruma K, Hata J etal. Clinical characteristics of Japanese dyspeptic patients: is the Rome III classification applicable? Scand. J. Gastroenterol. 2010; 45: 567-72.
8. Wang A, Liao X, Xiong L etal. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol. 2008; 8: 43.
9. Suzuki H, Gotoda T, Sasako M, Saito D. Detection of early gastric cancer: misunderstanding the role of mass screening. Gastric Cancer 2006; 9: 315-9.
10. Ryu E, Kim K, Cho MS, Kwon IG, Kim HS, Fu MR. Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs. 2010; 33: 3-10.
11. Karahocagil MK, Akdeniz H, Sunnetcioglu M etal. A familial outbreak of fascioliasis in Eastern Anatolia: a report with review of literature. Acta Trop. 2011; 118: 177-83.
12. Grazioli B, Matera G, Laratta C etal. Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study. World J. Gastroenterol. 2006; 12: 1941-4.
13. Upatham ES, Viyanant V, Kurathong S etal. Relationship between prevalence and intensity of Opisthorchis viverrini infection, and clinical symptoms and signs in a rural community in north-east Thailand. Bull. World Health Organ. 1984; 62: 451-61.
14. Khuroo NS, Khuroo MS. Gastric ascariasis presenting as unique dyspeptic symptoms in an endemic area. Am. J. Gastroenterol. 2010; 105: 1675-7.
15. Chen WX, Zhang WF, Li B etal. Clinical manifestations of patients with chronic pancreatitis. Hepatobiliary Pancreat. Dis. Int. 2006; 5: 133-7.
16. Gunsar F, Yilmaz S, Bor S etal. Effect of hypo- and hyperthyroidism on gastric myoelectrical activity. Dig. Dis. Sci. 2003; 48: 706-12.
17. Van Vlem B, Schoonjans R, Vanholder R, Vandamme W, De Vos M, Lameire N. Dyspepsia and gastric emptying in chronic renal failure patients. Clin. Nephrol. 2001; 56: 302-7.
18. Ashizawa N, Hashimoto T, Miyake T, Shizuku T, Imaoka T, Kinoshita Y. Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective? J. Gastroenterol. Hepatol. 2006; 21: 767-71.
19. Gonlachanvit S, Mahachai V, Chaiwatanarat T, Kullavanijaya P. Lack of effect of Helicobacter pylori on symptom improvement with a prokinetic medication, cisapride, in patients with non-ulcer dyspepsia. J. Med. Assoc. Thai. 2005; 88: 660-7.
20. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006; 131: 390-401; quiz 659-360.
21. Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J. Gastroenterol. Hepatol. 2010; 25: 479-86.
22. Parkman HP, Jones MP. Tests of gastric neuromuscular function. Gastroenterology 2009; 136: 1526-43.
23. Ghoshal UC, Singh R, Chang F-Y, Hou X, Wong BCY, Kachintorn U. Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. J. Neurogastroenterol. Motil 2011; 17: 235-44.
24. Li XB, Liu WZ, Ge ZZ etal. Analysis of clinical characteristics of dyspeptic symptoms in Shanghai patients. Chin. J. Dig. Dis. 2005; 6: 62-7.
25. Kwan AC, Bao TN, Chakkaphak S etal. Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J. Gastroenterol. Hepatol. 2003; 18: 796-802.
26. Kim JS, Lee KJ, Kim JH, Hahm KB, Cho SW. Functional gastrointestinal disorders in patients referred to specialist gastroenterologists in a tertiary hospital. Korean J. Neurogastroenterol. Motil. 2004; 10: 111-7.
27. Mahadeva S, Chia YC, Vinothini A, Mohazmi M, Goh KL. Cost-effectiveness of and satisfaction with a Helicobacter pylori "test and treat" strategy compared with prompt endoscopy in young Asians with dyspepsia. Gut 2008; 57: 1214-20.
28. Wai CT, Yeoh KG, Ho KY, Kang JY, Lim SG. Diagnostic yield of upper endoscopy in Asian patients presenting with dyspepsia. Gastrointest. Endosc. 2002; 56: 548-51.
29. Kawamura A, Adachi K, Takashima T etal. Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J. Gastroenterol. Hepatol. 2001; 16: 384-8.
30. Nakamura R, Saikawa Y, Takahashi T etal. Retrospective analysis of prognostic outcome of gastric cancer in young patients. Int. J. Clin. Oncol. 2011; 16: 328-34.
31. Ghoshal UC, Tiwari S, Dhingra S etal. Frequency of Helicobacter pylori and CagA antibody in patients with gastric neoplasms and controls: the Indian enigma. Dig. Dis. Sci. 2008; 53: 1215-22.
32. Shah SS, Bhatia SJ, Mistry FP. Epidemiology of dyspepsia in the general population in Mumbai. Indian J. Gastroenterol. 2001; 20: 103-6.
33. Ghoshal UC, Abraham P, Bhatt C etal. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J. Gastroenterol. 2008; 27: 22-8.
34. Okumura T, Tanno S, Ohhira M, Tanno S. Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan. J. Gastroenterol. 2010; 45: 187-94.
35. Hu WH, Wong WM, Lam CL etal. Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment. Pharmacol. Ther. 2002; 16: 2081-8.
36. Hori K, Matsumoto T, Miwa H. Analysis of the gastrointestinal symptoms of uninvestigated dyspepsia and irritable bowel syndrome. Gut Liver 2009; 3: 192-6.
37. Kitapçioǧlu G, Mandiracioǧlu A, Caymaz Bor C, Bor S. Overlap of symptoms of dyspepsia and gastroesophageal reflux in the community. Turk. J. Gastroenterol. 2007; 18: 14-9.
38. Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009; 79: 196-201.
39. Sperber AD. The challenge of cross-cultural, multi-national research: potential benefits in the functional gastrointestinal disorders. Neurogastroenterol. Motil. 2009; 21: 351-60.
40. Lu CL, Lang HC, Chang FY etal. Prevalence and health/social impacts of functional dyspepsia in Taiwan: a study based on the Rome criteria questionnaire survey assisted by endoscopic exclusion among a physical check-up population. Scand. J. Gastroenterol. 2005; 40: 402-11.
41. Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002; 50 (Suppl. 4): iv10-2.
42. Jeong JJ, Choi MG, Cho YS etal. Chronic gastrointestinal symptoms and quality of life in the Korean population. World J. Gastroenterol. 2008; 14: 6388-94.
43. Hu WH, Lam KF, Wong YH etal. The Hong Kong index of dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia. J. Gastroenterol. Hepatol. 2002; 17: 545-51.
44. Mahadeva S, Yadav H, Rampal S, Goh KL. Risk factors associated with dyspepsia in a rural Asian population and its impact on quality of life. Am. J. Gastroenterol. 2010; 105: 904-12.
45. Mahadeva S, Yadav H, Rampal S, Everett SM, Goh KL. Ethnic variation, epidemiological factors and quality of life impairment associated with dyspepsia in urban Malaysia. Aliment. Pharmacol. Ther. 2010; 31: 1141-51.
46. Mahadeva S, Wee HL, Goh KL, Thumboo J. The EQ-5D (Euroqol) is a valid generic instrument for measuring quality of life in patients with dyspepsia. BMC Gastroenterol. 2009; 9: 20.
47. Pan XP, Li YY, Sha WH, Yang FY. Psychological factors in functional dyspepsia and its treatment. Chin. J. Dig. Dis. 2000; 1: 17-20.
48. Mahadeva S, Goh KL. Anxiety, depression and quality of life differences between functional and organic dyspepsia. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 3): 49-52.
49. Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J. Gastroenterol. Hepatol. 2009; 24: 1601-7.
50. Lee KJ, Kindt S, Tack J. Pathophysiology of functional dyspepsia. Best Pract. Res. Clin. Gastroenterol. 2004; 18: 707-16.
51. Miwa H, Watari J, Fukui H etal. Current understanding of pathogenesis of functional dyspepsia. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 3): 53-60.
52. Mimidis K, Tack J. Pathogenesis of dyspepsia. Dig. Dis. 2008; 26: 194-202.
53. Kato M, Nishida U, Nishida M etal. Pathophysiological classification of functional dyspepsia using a novel drinking-ultrasonography test. Digestion 2010; 82: 162-6.
54. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr. Opin. Pharmacol. 2008; 8: 690-6.
55. Perri F, Clemente R, Festa V etal. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Am. J. Gastroenterol. 1998; 93: 2082-8.
56. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am. J. Gastroenterol. 2003; 98: 783-8.
57. Rahim MK, Durr-e-Sabih, Mateen A, Najam-Uddin, Yousaf M. Studies of gastric emptying time in patients with non-ulcer dyspepsia. Nucl. Med. Commun. 2007; 28: 852-8.
58. Aoki S, Haruma K, Kusunoki H etal. Evaluation of gastric emptying measured with the 13C-octanoic acid breath test in patients with functional dyspepsia: comparison with ultrasonography. Scand. J. Gastroenterol. 2002; 37: 662-6.
59. Duan LP, Zheng ZT, Li YN. A study of gastric emptying in non-ulcer dyspepsia using a new ultrasonographic method. Scand. J. Gastroenterol. 1993; 28: 355-60.
60. Shindo T, Futagami S, Hiratsuka T etal. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 2009; 79: 65-72.
61. Takamori K, Mizuta Y, Takeshima F etal. Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J. Clin. Gastroenterol. 2007; 41: 477-83.
62. Chang CS, Chen GH, Kao CH, Wang SJ, Peng SN, Huang CK. The effect of Helicobacter pylori infection on gastric emptying of digestible and indigestible solids in patients with nonulcer dyspepsia. Am. J. Gastroenterol. 1996; 91: 474-9.
63. Waldron B, Cullen PT, Kumar R etal. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32: 246-51.
64. Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig. Dis. Sci. 1998; 43: 2028-33.
65. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-55.
66. Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am. J. Gastroenterol. 2001; 96: 1422-8.
67. Wegener M, Börsch G, Schaffstein J, Reuter C, Leverkus F. Frequency of idiopathic gastric stasis and intestinal transit disorders in essential dyspepsia. J. Clin. Gastroenterol. 1989; 11: 163-8.
68. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-52.
69. Piessevaux H, Tack J, Walrand S, Pauwels S, Geubel A. Intragastric distribution of a standardized meal in health and functional dyspepsia: correlation with specific symptoms. Neurogastroenterol. Motil. 2003; 15: 447-55.
70. Hou XH, Li Q, Zhu L, Xie X, Chen JD. Correlation of gastric liquid emptying with various thresholds of sensation in healthy controls and patients with functional dyspepsia. Dig. Dis. Sci. 2004; 49: 188-95.
71. Rhee PL, Kim YH, Son HJ etal. The etiologic role of gastric hypersensitivity in functional dyspepsia in Korea. J. Clin. Gastroenterol. 1999; 29: 332-5.
72. Mertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998; 42: 814-22.
73. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526-35.
74. Vandenberghe J, Vos R, Persoons P, Demyttenaere K, Janssens J, Tack J. Dyspeptic patients with visceral hypersensitivity: sensitisation of pain specific or multimodal pathways? Gut 2005; 54: 914-9.
75. Lee KJ, Tack J. Duodenal implications in the pathophysiology of functional dyspepsia. J. Neurogastroenterol. Motil. 2010; 16: 251-7.
76. Son HJ, Rhee PL, Kim JJ, Koh KC, Paik SW, Rhee JC. Hypersensitivity to acid in ulcer-like functional dyspepsia. Korean J. Intern. Med. 1997; 12: 188-92.
77. Hammer J, Fuhrer M, Pipal L, Matiasek J. Hypersensitivity for capsaicin in patients with functional dyspepsia. Neurogastroenterol. Motil. 2008; 20: 125-33.
78. Li Y, Nie Y, Sha W, Su H. The link between psychosocial factors and functional dyspepsia: an epidemiological study. Chin. Med. J. 2002; 115: 1082-4.
79. Chen TS, Luo JC, Chang FY. Psychosocial-spiritual factors in patients with functional dyspepsia: a comparative study with normal individuals having the same endoscopic features. Eur. J. Gastroenterol. Hepatol. 2010; 22: 75-80.
80. Kang SG, Kim HJ, Lee SY, Cha MJ, Hwang HH. A study of anger, alexithymia, and depression in the functional dyspepsia. J. Korean Acad. Fam. Med. 2002; 23: 881-9.
81. Mujakovic S, de Wit NJ, van Marrewijk CJ etal. Psychopathology is associated with dyspeptic symptom severity in primary care patients with a new episode of dyspepsia. Aliment. Pharmacol. Ther. 2009; 29: 580-8.
82. Hsu YC, Liou JM, Liao SC etal. Psychopathology and personality trait in subgroups of functional dyspepsia based on Rome III criteria. Am. J. Gastroenterol. 2009; 104: 2534-42.
83. Hojo M, Miwa H, Yokoyama T etal. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J. Gastroenterol. 2005; 40: 1036-42.
84. Lee S, Park M, Choi S, Nah Y, Abbey SE, Rodin G. Stress, coping, and depression in non-ulcer dyspepsia patients. J. Psychosom. Res. 2000; 49: 93-9.
85. Moon JI, Go EH, Kim SY, Hwang IH. Comparison of stressful life events among peptic ulcer, not ulcer dyspepsia and control groups. J. Korean Acad. Fam. Med. 1999; 20: 804-11.
86. Hui WM, Shiu LP, Lam SK. The perception of life events and daily stress in nonulcer dyspepsia. Am. J. Gastroenterol. 1991; 86: 292-6.
87. Chen TS, Lee YC, Chang FY, Wu HC, Lee SD. Psychosocial distress is associated with abnormal gastric myoelectrical activity in patients with functional dyspepsia. Scand. J. Gastroenterol. 2006; 41: 791-6.
88. Cheng C, Hui WM, Lam SK. Coping style of individuals with functional dyspepsia. Psychosom. Med. 1999; 61: 789-95.
89. Cheng C, Yang FC, Jun S, Hutton JM. Flexible coping psychotherapy for functional dyspeptic patients: a randomized, controlled trial. Psychosom. Med. 2007; 69: 81-8.
90. Ahn MK, Lee SY, Kim YJ. The relationship between functional dyspepsia and family function. J. Korean Acad. Fam. Med. 1999; 20: 917-24.
91. Ochi M, Tominaga K, Iketani T etal. Perfectionism underlying psychological background correlated with the symptoms of functional dyspepsia. J. Gastroenterol. 2008; B: 699-704.
92. Talley NJ, Meineche-Schmidt V, Paré P etal. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment. Pharmacol. Ther. 1998; 12: 1055-65.
93. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst. Rev. 2006; (4): CD001960.
94. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment. Pharmacol. Ther. 2005; 21 (Suppl. 2): 32-6.
95. Wong WM, Wong BC, Hung WK etal. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 502-6.
96. Leung WK, Wu JC, Chan FK etal. Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. Am. J. Gastroenterol. 2007; 102: 1483-8.
97. Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim D, Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005; 54: 1370-6.
98. Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116: 515-20.
99. Lee KJ, Demarchi B, Demedts I, Sifrim D, Raeymaekers P, Tack J. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am. J. Gastroenterol. 2004; 99: 1765-73.
100. Misra SP, Broor SL. Is gastric acid responsible for the pain in patients with essential dyspepsia? J. Clin. Gastroenterol. 1990; 12: 624-7.
101. Lambert JR. The role of Helicobacter pylori in nonulcer dyspepsia. A debate-for. Gastroenterol. Clin. North Am. 1993; 22: 141-51.
102. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ 1999; 319: 1040-4.
103. el-Omar E, Penman I, Ardill JE, McColl KE. A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients. Gut 1995; 36: 534-8.
104. Sarnelli G, Cuomo R, Janssens J, Tack J. Symptom patterns and pathophysiological mechanisms in dyspeptic patients with and without Helicobacter pylori. Dig. Dis. Sci. 2003; 48: 2229-36.
105. Moayyedi P, Soo S, Deeks J etal. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000; 321: 659-64.
106. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 2001; 134: 361-9.
107. Miwa H, Hirai S, Nagahara A etal. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 2000; 14: 317-24.
108. Wong WM, Xiao SD, Hu PJ etal. Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. Aliment. Pharmacol. Ther. 2005; 21: 73-81.
109. Moayyedi P, Soo S, Deeks J etal. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst. Rev. 2006; (2): CD002096.
110. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007; 12: 541-6.
111. Mearin F, Perez-Oliveras M, Perello A etal. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98-104.
112. Li X, Chen H, Lu H etal. The study on the role of inflammatory cells and mediators in post-infectious functional dyspepsia. Scand. J. Gastroenterol. 2010; 45: 573-81.
113. Kindt S, Tertychnyy A, de Hertogh G, Geboes K, Tack J. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol. Motil. 2009; 21: 832-e56.
114. Tack J, Demedts I, Dehondt G etal. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122: 1738-47.
115. Camilleri CE, Carlson PJ, Camilleri M etal. A study of candidate genotypes associated with dyspepsia in a U.S. community. Am. J. Gastroenterol. 2006; 101: 581-92.
116. Holtmann G, Siffert W, Haag S etal. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004; 126: 971-9.
117. Tahara T, Arisawa T, Shibata T etal. Homozygous 825T allele of the GNB3 protein influences the susceptibility of Japanese to dyspepsia. Dig. Dis. Sci. 2008; 53: 642-6.
118. van Lelyveld N, Linde JT, Schipper M, Samsom M. Candidate genotypes associated with functional dyspepsia. Neurogastroenterol. Motil. 2008; 20: 767-73.
119. Oshima T, Nakajima S, Yokoyama T etal. The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med. Genet. 2010; 11: 13.
120. Arisawa T, Tahara T, Shibata T etal. Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia. Int. J. Mol. Med. 2007; 20: 717-23.
121. Tahara T, Arisawa T, Shibata T, Nakamura M, Wang F, Hirata I. COMT gene val158met polymorphism in patients with dyspeptic symptoms. Hepatogastroenterology 2008; 55: 979-82.
122. Tahara T, Arisawa T, Shibata T etal. 779 TC of CCK-1 intron 1 is associated with postprandial syndrome (PDS) in Japanese male subjects. Hepatogastroenterology 2009; 56: 1245-8.
123. Arisawa T, Tahara T, Shibata T etal. Genetic polymorphisms of cyclooxygenase-1 (COX-1) are associated with functional dyspepsia in Japanese women. J. Womens Health 2008; 17: 1039-43.
124. Tahara T, Shibata T, Wang F etal. A genetic variant of the p22PHOX component of NADPH oxidase C242T is associated with reduced risk of functional dyspepsia in Helicobacter pylori-infected Japanese individuals. Eur. J. Gastroenterol. Hepatol. 2009; 21: 1363-8.
125. Tahara T, Shibata T, Nakamura M etal. Homozygous TRPV1 315C influences the susceptibility to functional dyspepsia. J. Clin. Gastroenterol. 2010; 44: e1-7.
126. Watt AH, Lewis DJ, Horne JJ, Smith PM. Reproduction of epigastric pain of duodenal ulceration by adenosine. Br. Med. J. (Clin. Res. Ed) 1987; 294: 10-12.
127. Rao SS, Mudipalli RS, Mujica V, Utech CL, Zhao X, Conklin JL. An open-label trial of theophylline for functional chest pain. Dig. Dis. Sci. 2002; 47: 2763-8.
128. Barbera R, Feinle C, Read NW. Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig. Dis. Sci. 1995; 40: 1636-41.
129. Pilichiewicz AN, Feltrin KL, Horowitz M etal. Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am. J. Gastroenterol. 2008; 103: 2613-23.
130. Feinle-Bisset C, Horowitz M. Dietary factors in functional dyspepsia. Neurogastroenterol. Motil. 2006; 18: 608-18.
131. Lee KJ, Kim JH, Cho SW. Dietary influence on electro-gastrography and association of alterations in gastric myoelectrical activity with symptoms in patients with functional dyspepsia. J. Gastroenterol. Hepatol. 2006; 21: 59-64.
132. Chua AS, Bekkering M, Rovati LC, Keeling PW. Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia. Ann. N. Y. Acad. Sci. 1994; 713: 451-3.
133. Carvalho RV, Lorena SL, Almeida JR, Mesquita MA. Food intolerance, diet composition, and eating patterns in functional dyspepsia patients. Dig. Dis. Sci. 2010; 55: 60-5.
134. Gonlachanvit S. Are rice and spicy diet good for functional gastrointestinal disorders? J. Neurogastroenterol. Motil. 2010; 16: 131-8.
135. Hu ML, Wu KL, Chiu YC, Chiu KW, Changchien CS. Effect of ginger on patients with functional dyspepsia. J. Gastroenterol. Hepatol. 2009; 24 (Suppl. 1): A31.
136. Feinle-Bisset C, Vozzo R, Horowitz M, Talley NJ. Diet, food intake, and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia. Am. J. Gastroenterol. 2004; 99: 170-81.
137. Gwee KA, Bak YT, Ghoshal UC etal. Asian consensus on irritable bowel syndrome. J. Gastroenterol. Hepatol. 2010; 25: 1189-205.
138. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987; 1: 963-5.
139. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann. Intern. Med. 1995; 122: 107-12.
140. Haag S, Senf W, Tagay S etal. Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment. Pharmacol. Ther. 2007; 25: 973-86.
141. Zhang G, Li Y. Psychological intervention on improvement of depression emotion in patients with functional dyspepsia. Chin. J. Clin. Rehabil. 2006; 10: 160-1.
142. Sheu BS, Lin CY, Lin XZ, Shiesh SC, Yang HB, Chen CY. Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: a prospective controlled assessment. Am. J. Gastroenterol. 1996; 91: 441-7.
143. Dhali GK, Garg PK, Sharma MP. Role of anti-Helicobacter pylori treatment in H.pylori-positive and cytoprotective drugs in H.pylori-negative, non-ulcer dyspepsia: results of a randomized, double-blind, controlled trial in Asian Indians. J. Gastroenterol. Hepatol. 1999; 14: 523-8.
144. Hsu PI, Lai KH, Tseng HH etal. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment. Pharmacol. Ther. 2001; 15: 195-201.
145. Ang TL, Fock KM, Teo EK etal. Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. J. Gastroenterol. 2006; 41: 647-53.
146. Gwee KA, Teng L, Wong RK, Ho KY, Sutedja DS, Yeoh KG. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 2009; 21: 417-24.
147. Fock KM, Katelaris P, Sugano K etal. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009; 24: 1587-600.
148. Correa P, Fontham ET, Bravo JC etal. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J. Natl Cancer Inst. 2000; 92: 1881-8.
149. Uemura N, Mukai T, Okamoto S etal. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 639-42.
150. Mera R, Fontham ET, Bravo LE etal. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-40.
151. You WC, Brown LM, Zhang L etal. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J. Natl Cancer Inst. 2006; 98: 974-83.
152. Leung WK, Lin SR, Ching JY etal. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244-9.
153. Zhou L, Sung JJ, Lin S etal. A five-year follow-up study on the pathological changes of gastric mucosa after H.pylori eradication. Chin. Med. J. 2003; 116: 11-14.
154. Fuccio L, Zagari RM, Eusebi LH etal. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 2009; 151: 121-8.
155. Zhou L. Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication in China [Abstract]. Gastroenterology 2008; 134: A233.
156. Saito D, Boku N, Fujioka T, Fukuda Y. Impact of H.pylori eradication on gastric cancer prevention: endosopic results of the Japanese Intervention Trial (JITHP-Study). A randmized multi-center trial [Abstract]. Gastroenterology 2005; 128: A4.
157. Wong BC, Lam SK, Wong WM etal. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-94.
158. Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J. Gastroenterol. 2006; 12: 2661-6.
159. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 24-9.
160. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
161. Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract. Res. Clin. Gastroenterol. 2004; 18: 695-706.
162. Small PK, Loudon MA, Waldron B, Smith D, Campbell FC. Importance of reflux symptoms in functional dyspepsia. Gut 1995; 36: 189-92.
163. Bolling-Sternevald E, Lauritsen K, Aalykke C etal. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand. J. Gastroenterol. 2002; 37: 1395-402.
164. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. The Frosch Study Group. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 2000; 47: 473-80.
165. Gerson LB, Triadafilopoulos G. A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. Dig. Liver Dis. 2005; 37: 87-91.
166. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am. J. Med. 2004; 116: 740-8.
167. Hengels K. Therapeutic efficacy of 15mg lansoprazole mane in 269 patients suffering from non-ulcer dyspepsia (NUD): a multicentre, randomized, double-blind study. Gut 1998; 43: A89.
168. Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002; 50 (Suppl. 4): iv36-41.
169. Wang WH, Huang JQ, Zheng GF etal. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin. Gastroenterol. Hepatol. 2007; 5: 178-85, quiz 140.
170. Gwee KA, Hwang JE, Ho KY, Yeoh KG, Lum CF, Ang PK. In-practice predictors of response to proton pump inhibitor therapy in primary care patients with dyspepsia in an Asian population. J. Clin. Gastroenterol. 2008; 42: 134-8.
171. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80-7, 87.e1.
172. Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am. J. Gastroenterol. 2010; 105: 1531-7.
173. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol. 2010; 8: 504-8.
174. Hiyama T, Yoshihara M, Matsuo K etal. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J. Gastroenterol. Hepatol. 2007; 22: 304-10.
175. Tack J, Masclee A, Heading R etal. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol. Motil. 2009; 21: 272-80.
176. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia-100mg t.i.d. is an optimal dosage. Neurogastroenterol. Motil. 2010; 22: 618-e173.
177. Qin F, Huang X, Ren P. Chinese herbal medicine modified xiaoyao san for functional dyspepsia: meta-analysis of randomized controlled trials. J. Gastroenterol. Hepatol. 2009; 24: 1320-5.
178. Tatsuta M, Iishi H. Effect of treatment with liu-jun-zi-tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment. Pharmacol. Ther. 1993; 7: 459-62.
179. Kusunoki H, Haruma K, Hata J etal. Efficacy of rikkunshito, a traditional Japanese medicine (Kampo), in treating functional dyspepsia. Intern. Med. 2010; 49: 2195-202.
180. Soo S, Forman D, Delaney BC, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. Am. J. Gastroenterol. 2004; 99: 1817-22.
181. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am. J. Gastroenterol. 1998; 93: 160-5.
182. Dinan TG, Mahmud N, Rathore O etal. A double-blind placebo-controlled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia-are central serotoninergic responses enhanced? Aliment. Pharmacol. Ther. 2001; 15: 1613-8.
183. Chua A, Keating J, Hamilton D, Keeling PW, Dinan TG. Central serotonin receptors and delayed gastric emptying in non-ulcer dyspepsia. BMJ 1992; 305: 280-2.
184. Dinan TG, Yatham LN, Barry S, Chua A, Keeling PW. Serotonin supersensitivity: the pathophysiologic basis of non-ulcer dyspepsia? A preliminary report of buspirone/prolactin responses. Scand. J. Gastroenterol. 1990; 25: 541-4.
185. Miwa H, Nagahara A, Tominaga K etal. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am. J. Gastroenterol. 2009; 104: 2779-87.
186. van Kerkhoven LA, Laheij RJ, Aparicio N etal. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 2008; 6: 746-52, quiz 718.
187. Wu CY, Chou LT, Chen HP, Chang CS, Wong PG, Chen GH. Effect of fluoxetine on symptoms and gastric dysrhythmia in patients with functional dyspepsia. Hepatogastroenterology 2003; 50: 278-83.
188. Tanum L, Malt UF. Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder. Scand. J. Gastroenterol. 2000; 35: 935-41.
189. Kang JY, Tay HH, Guan R. Chronic upper abdominal pain: site and radiation in various structural and functional disorders and the effect of various foods. Gut 1992; 33: 743-8.
190. Pilichiewicz AN, Horowitz M, Holtmann GJ, Talley NJ, Feinle-Bisset C. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. Clin. Gastroenterol. Hepatol. 2009; 7: 317-22.
191. Feinle-Bisset C, Meier B, Fried M, Beglinger C. Role of cognitive factors in symptom induction following high and low fat meals in patients with functional dyspepsia. Gut 2003; 52: 1414-8.
192. Feinle C, Meier O, Otto B, D'Amato M, Fried M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001; 48: 347-55.
193. Feinle C, Fried M. Duodenal sensitivity to lipids and gastric motility: contribution to functional dyspepsia. Praxis 1998; 87: 1817-20.
194. Tsai SC, Hsieh JF, Ho YJ, Kao CH. Effects of butter and soybean oils on solid-phase gastric emptying in patients with functional dyspepsia. Abdom. Imaging 2000; 25: 35-7.
195. Barbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur. J. Gastroenterol. Hepatol. 1995; 7: 1051-7.
196. Mullan A, Kavanagh P, O'Mahony P, Joy T, Gleeson F, Gibney MJ. Food and nutrient intakes and eating patterns in functional and organic dyspepsia. Eur. J. Clin. Nutr. 1994; 48: 97-105.